Bristol-Myers Squibb is trading lower today, reflecting a broader downturn among its major pharmaceutical peers as most of the sector faces mild pressure. While recent commentary has highlighted the company as a potential value play trading at 9.4 times forward earnings, investors continue to weigh the long-term impact of patent cliffs and emerging competition in the cardiovascular and blood disorder markets. This cautious sentiment persists despite ongoing growth in the company's cardiovascular portfolio, such as the broader FDA label for Camzyos, as the stock remains 6.8% below its 50-day moving average.